Dataset Information

REGN-EB3: First Approval.

ABSTRACT: REGN-EB3 (INMAZEB^®, Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies-atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) -that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during an Ebola outbreak in the Democratic Republic of Congo, REGN-EB3 was recently approved by the US FDA as a treatment for Ebola virus infection. This article summarizes the milestones in the development of REGN-EB3 leading to this first approval for the treatment of infection caused by Zaire ebolavirus (Ebola virus) in adult and paediatric patients.

SUBMITTER: Markham A

PROVIDER: S-EPMC7799152 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

REGN-EB3: First Approval.

Markham Anthony A

Drugs 20210101 1

REGN-EB3 (INMAZEB<sup>®</sup>, Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies-atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) -that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during an Ebola outbreak in the Democratic Republic of Congo, REGN-EB3 was recently approved by the US FDA as a treatment for Ebola virus infection. This article summarizes the milestones in the development of REGN-EB3 le ...[more]

PMID: 33432551

Dataset Information

REGN-EB3: First Approval.

Publications

REGN-EB3: First Approval.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets